Différences
Ci-dessous, les différences entre deux révisions de la page.
| Les deux révisions précédentes Révision précédente Prochaine révision | Révision précédente | ||
|
acupuncture:evaluation:gastro-enterologie:06. syndrome du colon irritable [14 Apr 2025 17:57] Nguyen Johan [1.4.2.1. Fang 2025] |
acupuncture:evaluation:gastro-enterologie:06. syndrome du colon irritable [31 May 2025 17:20] (Version actuelle) Nguyen Johan [1.2.1.1. Wang 2025] |
||
|---|---|---|---|
| Ligne 202: | Ligne 202: | ||
| ==== Special Acupuncture Techniques ==== | ==== Special Acupuncture Techniques ==== | ||
| + | |||
| + | === Placebo response === | ||
| + | |||
| + | == Wang 2025 == | ||
| + | |||
| + | |||
| + | Wang Z, Chen Y, Li X, Lin L, Chen B, Chen M, Zheng H. Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis. Qual Life Res. 2025 Jun;34(6):1553-1568. https://doi.org/10.1007/s11136-025-03927- | ||
| + | ^Objectives| The impact of placebo response on health outcomes in various diseases, including IBS, is significant. To better understand the effect of different placebo administration methods on the observed outcomes in IBS studies, this meta-analysis aims to explore research findings on the degree of improvement.| | ||
| + | ^Methods| The meta-analysis included 45 randomized, double-blind, placebo-controlled clinical trials involving 5174 patients with confirmed IBS (excluding those with significant comorbidities). The trials were designed to compare the efficacy of different placebo interventions. The primary outcome was the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS), and secondary outcomes included the Irritable Bowel Syndrome Quality of Life Instrument (IBS-QoL) and the IBS Symptom Visual Analog Scale (VAS). An arm-based Bayesian network meta-analysis was performed to examine the relative effectiveness of the placebo interventions on the outcomes.| | ||
| + | ^Results| The analysis revealed that sham moxibustion exhibited the most significant efficacy in reducing IBS-SSS (MD -260.00, 95% CrIs: -288.00 to -232.00). Additionally, sham FMT resulted in significant improvements in IBS-QOL scores (MD 9.23, 95% CrIs - 3.69 to 22.30). Meanwhile, placebo tablet interventions were found to be the most effective in reducing VAS scores (MD 4.71, 95% CrIs, -1.14 to 11.10). Overall, this synthesis provides detailed insights into the effectiveness of placebos in addressing different outcome measures.| | ||
| + | ^Conclusions| Sham moxibustion appears to provide subjective benefits for patients' IBS symptoms. However, the evidence for its efficacy is less robust compared to other interventions, as assessed by GRADE. Understanding the placebo effect in IBS management is crucial for clinical practice and drug development, particularly in placebo comparisons.| | ||
| + | |||
| + | |||
| + | === Acupoint application === | ||
| + | |||
| + | == Wang 2025 == | ||
| + | |||
| + | Wang Q, Zhao L, Liu J, Chen L, Zhang B, Zhang Q, Lu Y, Gao Y, Zheng X, He Z, Jing S. Meta analysis of clinical efficacy of acupoint application in the treatment of irritable bowel syndrome. Afr Health Sci. 2024 Dec;24(4):351-361. https://doi.org/10.4314/ahs.v24i4.44 | ||
| + | |||
| + | ^ Purpose| The clinical efficacy of acupoint application in the treatment of irritable bowel syndrome (IBS) was evaluated by Meta-analysis.| | ||
| + | ^Method| Computer searched Chinese and English databases for the randomized controlled trials (RCTs) and quasi-randomized controlled trials (CCTs) of TCM external therapy, acupoint application, TCM external application, navel sticking and their combination therapy in the treatment of IBS. The search period is from the establishment of the database to December 2022. The literature was screened independently by 2 researchers according to the standard of nano-ranking, and the data of the other 5 researchers were proofread, screened and extracted. After that, the bias risk of the included study was evaluated, and the data were analysed by RevMan 5.4. software.| | ||
| + | ^Result| (1) A total of 1842 patients, were included in **25 randomized controlled trials**, including the acupoint application treatment group (n=928) and conventional therapy control group (n = 914).(2) The quality of the literature method shows that there are 5 high-quality literatures with a score of 4-7, 20 low-quality literatures with a score of 1-3 and few high-quality literatures;(3) In terms of effectiveness, compared with the western medicine control group, the total odds ratio OR [95 % CI] of the total effective rate of the acupoint application treatment group was 4.77 [3.68, 6.20], and the difference was statistically significant (P < 0.05). Shenque, Zhongwan, Pishu and Zusanli are the most commonly used.(4) In terms of literature bias, 2 studies used envelopes to hide, which belonged to "low risk"; 9 studies were blindly implemented and evaluated as "unclear"; and 6 studies were rated as "high risk" because cases fell off but were not reported. The funnel plot shows that the study is scatter symmetrical, the probability of publication bias is small, and the conclusion is reliable.| | ||
| + | ^Conclusion| Acupoint application can improve the effective clinical rate of IBS with fewer adverse reactions, better patient compliance and fewer adverse reactions, but it still needs to be confirmed by high-quality multicenter, large sample randomized controlled trials.| | ||
| === Moxibustion === | === Moxibustion === | ||
| Ligne 410: | Ligne 433: | ||
| ===== Clinical Practice Guidelines ===== | ===== Clinical Practice Guidelines ===== | ||
| | ⊕ positive recommendation (regardless of the level of evidence reported) \\ Ø negative recommendation (or lack of evidence) | | | ⊕ positive recommendation (regardless of the level of evidence reported) \\ Ø negative recommendation (or lack of evidence) | | ||
| + | |||
| + | |||
| + | |||
| + | ==== European and North American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN and NASPGHAN) 2025 Ø==== | ||
| + | |||
| + | Groen J, Gordon M, Chogle A, Benninga M, Borlack R, Borrelli O, Darbari A, Dolinsek J, Khlevner J, Di Lorenzo C, Person H, Sanghavi R, Snyder J, Thapar N, Vlieger A, Sinopoulou V, Tabbers M, Saps M. ESPGHAN/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain-not otherwise specified in children aged 4-18 years. J Pediatr Gastroenterol Nutr. 2025 May 30. https://doi.org/10.1002/jpn3.70070 | ||
| + | | **children aged 4-18 years**. All of the following therapies were therefore not suggested as treatment options. **Acupuncture**…| | ||
| + | |||
